ArticleFrontiers in bioengineering and biotechnology2021
A Colorectal Cancer 3D Bioprinting Workflow as a Platform for Disease Modeling and Chemotherapeutic Screening.
Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- 3D bioprinting for cancer modeling and drug screening.Biomarker research · 2026Review
- A Multicellular 3D GelMA-Based Colorectal Cancer Model for Chemotherapeutic Responses.Macromolecular bioscience · 2026Article
- Tailorable porous collagen hydrogels as a physiologically relevant platform for extrachromosomal DNA-associated colorectal cancer research.Theranostics · 2026Article
- From mono- to multi-cellularFrontiers in cell and developmental biology · 2026Review
- Article
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025Review
- 3D Bioprinting and Artificial Intelligence for Tumor Microenvironment Modeling: A Scoping Review of Models, Methods, and Integration Pathways.Molecular pharmaceutics · 2025Article
- Review
- Developing Patient-Derived 3D-Bioprinting models of pancreatic cancer.Journal of advanced research · 2025Article
- Exploring the Complexity of Cutaneous Squamous CellCarcinoma Microenvironment: Focus on Immune Cell Roles by Novel 3D In Vitro Models.Life (Basel, Switzerland) · 2025Review
- Patient-derived mini-colons enable long-term modeling of tumor-microenvironment complexity.Nature biotechnology · 2025Article
- Establishing a Bioink Assessment Protocol: GelMA and Collagen in the Bioprinting of a PotentialACS biomaterials science & engineering · 2025Article
- Harnessing 3D models to uncover the mechanisms driving infectious and inflammatory disease in the intestine.BMC biology · 2024Review
- Advancements in 3D In Vitro Models for Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- High Hopes for the Biofabrication of Articular Cartilage-What Lies beyond the Horizon of Tissue Engineering and 3D Bioprinting?Biomedicines · 2024Review
- 3D bioprinted CRC model brings to light the replication necessity of an oncolytic vaccinia virus encodingFrontiers in oncology · 2024Article
- The application of organoids in colorectal diseases.Frontiers in pharmacology · 2024Review
- Prediction of Clinical Precision Chemotherapy by Patient-Derived 3D Bioprinting Models of Colorectal Cancer and Its Liver Metastases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Review
- World's First Long-Term Colorectal Cancer Model by 3D Bioprinting as a Mechanism for Screening Oncolytic Viruses.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common malignancy and has recently moved up to the second leading cause of death among carcinomas. Prognosis, especially for advanced diseases or certain molecular subtypes of CRC, remains poor, which highlights the urgent need for better therapeutic strategies. However, currently, as little as 0.1% of all drugs make it from bench to bedside because of the inherently high false-positive and false-negative rates of current preclinical and clinical drug testing data. Therefore, the success of developing novel treatment agents lies in the introduction of improved preclinical disease models which resemble
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.